Company / PP&E (Net)
Astria Therapeutics, Inc. PP&E (Net) History
FY2015-FY2018 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$56.0K
FY2018
5-year range
-
FY2015-FY2018
Trend
-82.6%
vs FY2017
Sector context
#188 of 193
Health Care
What the data says
Among 193 Health Care companies, Astria Therapeutics, Inc. is in the bottom 3% for pp&e (net). Declined from $568,000 to $56,000 over the past 2 years.
Based on SEC 10-K filings.
$56,000 in FY2018 with a 3-year CAGR of -51.9%.
Declined from $568,000 to $56,000 over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -51.9%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 3% in Health CareTop 97% of 193This company $56.0K Sector average $777.6M
▼
-100.0% below sector average
Key checks
Key Insights
- 3-year CAGR of -51.9%, indicating a declining trend.
- In FY2018, pp&e (net) decreased 82.6% year-over-year.
- Ranks #188 out of 193 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 5.45 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | $56.0K | -82.6% |
| FY2017 | $321.0K | -43.5% |
| FY2016 | $568.0K | +12.7% |
| FY2015 | $504.0K | +75.0% |
As of FY2018 · SEC 10-K · Updated Feb 28, 2026